Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 37 of 37 entries

Molecular Profile	Indication/Tumor Type	Response Type	Relevant Treatment Approaches	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
EML4 - ALK ALK I1171N	lung non-small cell carcinoma	predicted - resistant		Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with non-small cell lung carcinoma harboring EML4-ALK demonstrated tumor regression when treated with Alecensa (alectinib), but progressed seven months later, and was found to harbor a secondary resistance mutation, ALK I1171N (PMID: 25393798).	25393798
EML4 - ALK ALK I1171N	lung adenocarcinoma	predicted - resistant		Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, ALK I1171N was identified in post-progression biopsy in a patient with metastatic lung adenocarcinoma harboring EML4-ALK (e6:e20), who previously responded to Alecensa (alectinib) (PMID: 36864442).	36864442
EML4 - ALK ALK I1171N	lung adenocarcinoma	predicted - sensitive		Ensartinib	Case Reports/Case Series	Actionable	In a clinical case study, Ensacove (ensartinib) treatment resulted in a decrease in the liver lesions after 20 days of treatment in a patient with metastatic lung adenocarcinoma harboring EML4-ALK (e6:e20) and ALK I1171N (PMID: 36864442).	36864442
EML4 - ALK ALK I1171N	inflammatory myofibroblastic tumor	predicted - resistant		Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, ALK I1171N was identified on post-progression biopsy in a patient with inflammatory myofibroblastic tumor of the lung harboring EML4-ALK, who previously responded to Alecensa (alectinib) (PMID: 37255276).	37255276
EML4 - ALK ALK I1171N	inflammatory myofibroblastic tumor	predicted - sensitive	Lorlatinib	Lorlatinib	Case Reports/Case Series	Actionable	In a clinical case study, Lorbrena (lorlatinib) treatment resulted in near resolution of the pleural effusion and decrease in pleural mass in a patient with inflammatory myofibroblastic tumor of the lung harboring EML4-ALK and ALK I1171N (PMID: 37255276).	37255276
EML4 - ALK ALK I1171N	pulmonary neuroendocrine tumor	predicted - resistant		Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, ALK I1171N was identified in post-progression biopsy in a patient with metastatic pulmonary atypical carcinoid tumor harboring EML4-ALK (e6:e20) who previously responded to Alecensa (alectinib) treatment (PMID: 35832448).	35832448
EML4 - ALK ALK I1171N	pulmonary neuroendocrine tumor	predicted - sensitive	Ceritinib	Ceritinib	Case Reports/Case Series	Actionable	In a clinical case study, Zykadia (ceritinib) treatment resulted in response after 1 month of treatment with tumor shrinkage in a patient with metastatic pulmonary atypical carcinoid tumor harboring EML4-ALK (e6:e20) and ALK I1171N (PMID: 35832448).	35832448
EML4 - ALK ALK I1171N	lung adenocarcinoma	predicted - resistant		Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, ALK I1171N was identified at the time of progression in a patient with metastatic lung adenocarcinoma harboring EML4-ALK who previously demonstrated a partial response on Alecensa (alectinib) treatment (PMID: 38623748).	38623748
EML4 - ALK ALK I1171N	lung adenocarcinoma	predicted - sensitive	Brigatinib	Brigatinib	Case Reports/Case Series	Actionable	In a clinical case study, Alunbrig (brigatinib) treatment resulted in stable disease with a progression-free survival of 17 months in a patient with metastatic lung adenocarcinoma harboring EML4-ALK and ALK I1171N (PMID: 38623748).	38623748
EML4 - ALK ALK I1171N	lung adenocarcinoma	predicted - sensitive	Lorlatinib	Lorlatinib	Case Reports/Case Series	Actionable	In a clinical case study, Lorbrena (lorlatinib) treatment resulted in a partial response in all lesions including lesions within the CNS with a progression-free survival of 14 months in a patient with metastatic lung adenocarcinoma harboring EML4-ALK and ALK I1171N (PMID: 38623748).	38623748
EML4 - ALK ALK I1171N	lung non-small cell carcinoma	predicted - resistant		Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, ALK I1171N was identified in the post-progression biopsy of a patient with non-small cell lung cancer harboring EML4-ALK who was treated with Alecensa (alectinib) (PMID: 33166721).	33166721
EML4 - ALK ALK I1171N	sarcoma	predicted - resistant		Alectinib	Case Reports/Case Series	Actionable	In a Phase II trial, ALK I1171N was identified on post-progression biopsy in a patient with metastatic non-myofibroblastic sarcoma harboring EML4-ALK (e2:e20), who previously achieved a partial response on Alecensa (alectinib) treatment (PMID: 39188081).	39188081
EML4 - ALK ALK I1171N	sarcoma	predicted - sensitive	Lorlatinib	Lorlatinib	Case Reports/Case Series	Actionable	In a clinical case study, Lorbrena (lorlatinib) treatment resulted in a partial response in a patient with metastatic non-myofibroblastic sarcoma harboring EML4-ALK (e2:e20) and ALK I1171N (PMID: 39188081).	39188081
EML4 - ALK ALK I1171N	lung non-small cell carcinoma	predicted - resistant		Alectinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Alecensa (alectinib) failed to inhibit growth of patient-derived non-small cell lung cancer cells harboring EML4-ALK with ALK I1171N in culture, and did not induce tumor regression or reduce Alk phosphorylation in xenograft models (PMID: 33627640).	33627640
EML4 - ALK ALK I1171N	lung non-small cell carcinoma	sensitive		Gilteritinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) inhibited growth of patient-derived non-small cell lung cancer cells harboring EML4-ALK with ALK I1171N in culture, and induced tumor regression and suppressed Alk phosphorylation and downstream signaling in xenograft models (PMID: 33627640).	33627640
EML4 - ALK ALK I1171N	lung non-small cell carcinoma	resistant		Crizotinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived non-small cell lung cancer cells harboring EML4-ALK with ALK I1171N were resistant to treatment with Xalkori (crizotinib) in culture (PMID: 33627640).	33627640
EML4 - ALK ALK I1171N	lung non-small cell carcinoma	sensitive	Lorlatinib	Lorlatinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Lorbrena (lorlatinib) inhibited cell viability, decreased downstream ALK signaling, and induced apoptosis in patient-derived non-small cell lung cancer cells harboring EML4-ALK with ALK I1171N in culture (PMID: 33627640).	33627640
EML4 - ALK ALK I1171N	lung non-small cell carcinoma	resistant		Entrectinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived non-small cell lung cancer cells harboring EML4-ALK with ALK I1171N were resistant to treatment with Rozlytrek (entrectinib) in culture (PMID: 33627640).	33627640
EML4 - ALK ALK I1171N	Advanced Solid Tumor	predicted - resistant		Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated a decreased response to treatment with Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).	27432227
EML4 - ALK ALK I1171N	Advanced Solid Tumor	sensitive	Ceritinib	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).	27432227
EML4 - ALK ALK I1171N	Advanced Solid Tumor	resistant		Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated resistance to treatment with Alecensa (alectinib) in culture (PMID: 27432227).	27432227
EML4 - ALK ALK I1171N	Advanced Solid Tumor	sensitive	Brigatinib	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Alunbrig (brigatinib) in culture (PMID: 27432227).	27432227
EML4 - ALK ALK I1171N	Advanced Solid Tumor	conflicting	Lorlatinib	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Lorbrena (lorlatinib) in culture (PMID: 27432227).	27432227
EML4 - ALK ALK I1171N	Advanced Solid Tumor	resistant		TPX-0131	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK I1171N in the context of EML4-ALK were resistant to TPX-0131 in culture (PMID: 34158340).	34158340
EML4 - ALK ALK I1171N	Advanced Solid Tumor	predicted - resistant		Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171N were resistant to Xalkori (crizotinib) in culture (PMID: 33627640).	33627640
EML4 - ALK ALK I1171N	Advanced Solid Tumor	resistant		Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171N were resistant to treatment with Alecensa (alectinib) in culture (PMID: 33627640).	33627640
EML4 - ALK ALK I1171N	Advanced Solid Tumor	sensitive	Ceritinib	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited viability of transformed cells expressing EML4-ALK with ALK I1171N in culture (PMID: 33627640).	33627640
EML4 - ALK ALK I1171N	Advanced Solid Tumor	sensitive	Brigatinib	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited viability of transformed cells expressing EML4-ALK with ALK I1171N in culture (PMID: 33627640).	33627640
EML4 - ALK ALK I1171N	Advanced Solid Tumor	conflicting	Lorlatinib	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171N demonstrated resistance to treatment with Lorbrena (lorlatinib) in culture (PMID: 33627640).	33627640
EML4 - ALK ALK I1171N	Advanced Solid Tumor	resistant		Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171N were resistant to Rozlytrek (entrectinib) in culture (PMID: 33627640).	33627640
EML4 - ALK ALK I1171N	Advanced Solid Tumor	sensitive		Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) inhibited viability of transformed cells expressing EML4-ALK with ALK I1171N in culture (PMID: 33627640).	33627640
EML4 - ALK ALK I1171N	Advanced Solid Tumor	sensitive		Iruplinalkib	Preclinical - Cell culture	Actionable	In a preclinical study, Iruplinalkib (WX-0593) treatment inhibited viability of transformed cells expressing EML4-ALK with ALK I1171N in culture (PMID: 35421578).	35421578
EML4 - ALK ALK I1171N	Advanced Solid Tumor	sensitive	Brigatinib	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) treatment inhibited viability of transformed cells expressing EML4-ALK with ALK I1171N in culture (PMID: 35421578).	35421578
EML4 - ALK ALK I1171N	Advanced Solid Tumor	resistant		Repotrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171N were resistant to Augtyro (repotrectinib) in culture (PMID: 36201110).	36201110
EML4 - ALK ALK I1171N	Advanced Solid Tumor	sensitive		Ensartinib	Preclinical - Cell culture	Actionable	In a preclinical study, Ensacove (ensartinib) inhibited Alk phosphorylation and viability of transformed cells expressing EML4-ALK with ALK I1171N in culture (PMID: 36201110).	36201110
EML4 - ALK ALK I1171N	Advanced Solid Tumor	resistant		TPX-0131	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171N were resistant to TPX-0131 in culture (PMID: 36201110).	36201110
EML4 - ALK ALK I1171N	Advanced Solid Tumor	predicted - sensitive		NVL-655	Preclinical	Actionable	In a preclinical study, NVL-655 moderately inhibited viability cells expressing EML4-ALK and ALK I1171N in culture and inhibited tumor growth in a transplant model (PMID: 39269178).	39269178

Showing 1 to 37 of 37 entries

Filter rows:

Profile Name	EML4 - ALK ALK I1171N
Gene Variant Detail	ALK I1171N (gain of function) EML4 - ALK (gain of function)
Relevant Treatment Approaches	Brigatinib Ceritinib Lorlatinib

Molecular Profile Detail

Contact

Filtering

Sorting